Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 9 recruiting now early-phase tilt

Mental Disorder: early-phase trial registry

9 of 22 indexed Mental Disorder trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #756 of 28,707 conditions by registered trial count.

22 US clinical trials · 9 currently recruiting · #756 of 28,707 conditions by registered trial count

Mental Disorder: 22 US clinical trials tracked, 9 recruiting.

Mental Disorder is the subject of 22 registered US clinical trials on ClinicalTrials.gov, 9 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is Otsuka Pharmaceutical Development & Commercialization, running 3 of these trials.

Enrollment posture brief

Registry condition mental-disorder

OPEN 9 | RECR 41% | LATE 2 | EARLY 5 | RANK #756 | SPON 3

Nearest open-share peer: Brain Injuries, Traumatic (41% recruiting · 22 trials)

Advanced Melanoma63.6%Mental Disorder (this)41%Acute Myeloid Leukemia Arisi18.2%Adenocarcinoma of the Prosta0%Adult Acute Myeloid Leukemia0%
Open-enrollment share among volume-matched conditions near Mental Disorder

Mental Disorder lists 9 open slots (41% of 22 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Mental Disorder on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Mental Disorder recruits in line with its size-band peers.

    9 of 22 indexed trials (40.9%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Mental Disorder trials is spread across many organizations.

    Otsuka Pharmaceutical Development & Commercialization accounts for 3 of 22 trials (13.6%). 16 distinct sponsors appear on at least one study for this condition label.

  3. Typical Mental Disorder enrolment sits around 150 participants.

    Median target enrolment is 150 among the 22 trials that report a genuine target (sentinel values excluded). 9 of those (40.9%) plan for fewer than 100 participants.

  4. Mental Disorder research is mostly interventional.

    18 interventional and 4 observational studies make up this index (81.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11Phase 24Phase 32

Open and recent trials

22 total, page 1 of 1

RECRUITING Phase 2 200 participants

GLP-1R Agonist Treatment for Opioid Use Disorder

Milton S. Hershey Medical Center

NCT06548490

RECRUITING Phase 2 180 participants

Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness

Brigham and Women's Hospital

NCT06376734

RECRUITING NA 150 participants

Transdiagnostic Behavior Therapy Vs TAU for Adjustment Disorder Following Traumatic Event Exposure

The University of Texas Health Science Center, Houston

NCT06433271

RECRUITING NA 100 participants

Enhancing Immune Health Randomized Controlled Trial

University of Illinois at Chicago

NCT05639881

RECRUITING NA 80 participants

Preliminary Efficacy Trial of a Digital Intervention for Depression and Cannabis Use

Massachusetts General Hospital

NCT06878859

RECRUITING NA 60 participants

Healthy ReStart Intervention to Improve Health and Functioning

University of Illinois at Chicago

NCT05544344

RECRUITING NA 60 participants

Brain Stimulation to the Hippocampus in Schizophrenia

Stanford University

NCT07010614

RECRUITING 40 participants

Passive Sensor Identification of Digital Biomarkers to Assess Effects of Orally Administered Nicotinamide Riboside

Mclean Hospital

NCT05245903

RECRUITING NA 24 participants

ACT for HIV-Positive Men

University of Alabama at Birmingham

NCT06625437

ACTIVE NOT RECRUITING NA 750 participants

FCT Study: Reducing the Need for Out-of-Home Placements

Duke University

NCT03641664

ACTIVE NOT RECRUITING Phase 2 40 participants

Individualized Functional Connectivity Targeting in aiTBS for Depression

Brigham and Women's Hospital

NCT05680727

ACTIVE NOT RECRUITING Phase 2 15 participants

Psilocybin for the Treatment of Veterans With Post-Traumatic Stress Disorder

Ohio State University

NCT05554094

ACTIVE NOT RECRUITING Early Phase 1 10 participants

Testing a Transdiagnostic TMS Treatment Target

Brigham and Women's Hospital

NCT06282146

COMPLETED 2,400 participants

Mapping Personality Traits to Genes

National Institute of Mental Health (NIMH)

NCT00001414

COMPLETED NA 1,000 participants

Systems Aligning for Equity (SAFE) Spaces

New York University

NCT05658068

COMPLETED 450 participants

Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo

Otsuka Pharmaceutical Development & Commercialization

NCT02192554

COMPLETED Phase 3 433 participants

A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2 Fixed Doses of Brexpiprazole in the Treatment of Alzheimer's Agitation

Otsuka Pharmaceutical Development & Commercialization

NCT01862640

COMPLETED Phase 3 270 participants

Safety and Tolerability Study of Flexible Dosing of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type

Otsuka Pharmaceutical Development & Commercialization

NCT01922258

COMPLETED NA 234 participants

Peer Navigators to Address Obesity-Related Concerns for African Americans With Serious Mental Illness

Illinois Institute of Technology

NCT03382782

COMPLETED 150 participants

Neuropsychiatric Effects of Interferon-Alpha and Ribavirin

National Institute of Mental Health (NIMH)

NCT00001547

COMPLETED NA 108 participants

HIV/STI Prevention Among Black Adolescents With Mental Illnesses (Project GOLD)

University of Pennsylvania

NCT03348813

COMPLETED NA 74 participants

Family Promoting Positive Emotions Pilot Study

Vanderbilt University

NCT05223842

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 4
Phase 3 2

Named interventions

Most-linked intervention names on Mental Disorder records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Brexpiprazole, OPC-34712 Drug
2 trials
transcranial magnetic stimulation Procedure
2 trials
Integrated Care Behavioral
1 trials
BWLI & Peer Navigator Behavioral
1 trials
BWLI Behavioral
1 trials
General Health Control Intervention Behavioral
1 trials
HIV/STI Prevention Intervention Behavioral
1 trials
Written Information Behavioral
1 trials

US sites by state

Facility locations filed on Mental Disorder trials. A trial with sites in several states counts in each.

Massachusetts 7 trials
California 5 trials
New York 3 trials
Maryland 3 trials
Illinois 3 trials
Florida 3 trials
Alabama 3 trials
Pennsylvania 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Mental Disorder page

22 registered trials, 9 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Mental Disorder condition card totals 22 registered trials; most-linked intervention Brexpiprazole, OPC-34712; top US site state Massachusetts. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.